Stanford University, $25,000
This team is developing a cold plasma device that selectively kills infection-causing microorganisms without damage to other cells or tissues. The major benefit of this technology over current methods of disinfection is its potential effectiveness against the most robust infectious organisms, including drug-resistant bacterial strains, fungi and biofilms.